1
|
Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP. Academic Cancer Center Phase I Program Development. Oncologist 2017; 22:369-374. [PMID: 28314841 PMCID: PMC5388388 DOI: 10.1634/theoncologist.2016-0409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 01/09/2017] [Indexed: 11/23/2022] Open
Abstract
This commentary assesses the factors necessary for the effectiveness of academic phase I cancer programs. The metrics presented here may be useful as a rubric for new and established programs. Multiple factors critical to the effectiveness of academic phase I cancer programs were assessed among 16 academic centers in the U.S. Successful cancer centers were defined as having broad phase I and I/II clinical trial portfolios, multiple investigator‐initiated studies, and correlative science. The most significant elements were institutional philanthropic support, experienced clinical research managers, robust institutional basic research, institutional administrative efforts to reduce bureaucratic regulatory delays, phase I navigators to inform patients and physicians of new studies, and a large cancer center patient base. New programs may benefit from a separate stand‐alone operation, but mature phase I programs work well when many of the activities are transferred to disease‐oriented teams. The metrics may be useful as a rubric for new and established academic phase I programs.
Collapse
Affiliation(s)
- Arthur E Frankel
- University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | | | - George J Weiner
- Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, USA
| | - Robert Chen
- City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Nilofer S Azad
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
| | - Michael J Pishvaian
- Georgetown University Medical Center, Lombardi Cancer Center, Washington DC, USA
| | - John A Thompson
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, USA
| | | | | | - A Craig Lockhart
- Alvin J. Siteman Cancer Center at the Washington University School of Medicine, St. Louis, Missouri, USA
| | | | - Jordan D Berlin
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | - John Sarantopoulos
- Institute for Drug Development at the Cancer Therapy and Research Center of the University of Texas Health Science Center, San Antonio, Texas, USA
| | - Matthew Riese
- Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Mansoor N Saleh
- Comprehensive Cancer Center at the University of Alabama, Birmingham, Alabama, USA
| | - Chul Ahn
- University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Eugene P Frenkel
- University of Texas Southwestern Medical Center, Dallas, Texas, USA
| |
Collapse
|